Evonik stock falls after Morgan Stanley downgrade and site closures
Published on 09/15/2026 at 18:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evonik Industries AG stock (ISIN DE000EVNK013) is under pressure on September 15, 2026, with the Xetra-listed shares trading near EUR 17.50, down around 3 percent from the prior close as investors react to a Morgan Stanley downgrade and recent German site closures in a weak chemical-sector environment.
Morgan Stanley downgrade hits Evonik stock
According to MarketScreener on September 15, 2026, Morgan Stanley downgraded its rating on Evonik Industries AG, contributing to a spot price of about EUR 17.50 on Tradegate with a daily decline of 2.56 percent and a year-to-date gain of 30.99 percent.
As WTBX reports on September 15, 2026, Evonik Industries shed around 3 percent after Morgan Stanley cut its view on the stock, underlining how the downgrade acts as a direct catalyst for the latest share-price weakness.
In addition, sector coverage from n-tv on September 15, 2026 notes that Evonik, Syensqo, Arkema, Wacker Chemie and BASF shares each fell between 2 and 3 percent, with the European chemical index losing a little over 1 percent, showing that the Morgan Stanley move comes against a broadly weak backdrop.
Stock retreats from recent mid-September levels
Earlier in the month, Evonik stock had traded higher, with a closing level of around EUR 18.08 on Xetra on September 11, 2026 and an example intraday quote of EUR 18.075 accompanied by a gain of about 1.20 percent that day, as described in a corporate-news overview from Ad hoc news.
Per data cited in the same overview, the latest Xetra close before the current downdraft was about EUR 17.90 on September 14, 2026, implying that the drop to roughly EUR 17.50 on September 15, 2026 represents a decline of about 2.2 percent compared with that last completed session.
Real-time figures compiled by Investing.com show Evonik shares at approximately EUR 17.46 on September 15, 2026, down 2.81 percent on the day, with a day range between EUR 17.33 and EUR 17.64 and a 52-week range between EUR 12.49 and EUR 19.21, indicating that the current level sits clearly below the recent 52-week high but still markedly above the lows of the past year.
Restructuring and chemical-sector pressure provide context
Beyond the rating change, operational restructuring adds to the cautious sentiment. According to chemXplore in a report dated September 11, 2026, Evonik plans to consolidate German production by closing its Hamburg and Bitterfeld sites, affecting around 90 employees and shifting Hamburg roles to Essen while Bitterfeld is scheduled to shut down by end-April 2027.
A separate article from K-Zeitung on September 15, 2026 also discusses the closure of the Hamburg and Bitterfeld locations, highlighting that Evonik aims to concentrate customer supply on larger German sites while employee discussions are ongoing, which investors interpret as a sign of continued portfolio adjustment in a challenging market.
Sector commentary from MarketScreener on September 15, 2026 points out that the chemical industry remains weak despite some earlier positive signals, suggesting that Evonik’s downgrade and price decline are part of a broader pattern of cautious views on the sector.
Recent analyst signals and valuation picture
Analyst sentiment around Evonik had already been guarded before the Morgan Stanley move. As Ad hoc news summarized on September 14, 2026, JP Morgan Chase reiterated its Underweight rating on Evonik stock on September 11, 2026 at a share price of around EUR 17.93, underlining a view of limited upside at then-prevailing valuations.
The same Marketscreener overview reporting the Morgan Stanley downgrade also cites a consensus average price target of EUR 18.30 for Evonik with a prior closing price of EUR 17.96, implying that the median analyst expectation is only about 1.9 percent above that earlier close, a modest potential return that fits the overall cautious stance.
Evonik’s market capitalization is indicated at roughly EUR 8,000,000,000 as of September 11, 2026 in the Ad hoc news corporate data, so the fall from EUR 18.08 on that date to close to EUR 17.50 on September 15, 2026 shaves several hundred million euros off the company’s equity value, even though the stock remains significantly above its 52-week low near EUR 12.49.
Reporting and event outlook
While the current share-price reaction is driven mainly by the Morgan Stanley rating change and restructuring headlines, investors are also watching for upcoming reporting dates and potential guidance updates. The recent consolidation decision for Hamburg and Bitterfeld, with a timeline stretching into 2027, suggests that restructuring charges and efficiency gains could feature in future quarterly releases.
Sector forecasts referenced by MarketScreener note that Germany’s chemical association expects revenue growth for 2026 but warns that geopolitical conflicts can mask underlying difficulties, a risk factor that investors in Evonik will factor into their medium-term expectations alongside company-specific measures.
Evonik stock level on Xetra
On Xetra, Evonik stock most recently closed at about EUR 17.90 on September 14, 2026, with the latest indications around EUR 17.40 to EUR 17.50 on September 15, 2026 representing a decline of roughly 2 to 3 percent on the day and placing the shares around 9 percent below the 52-week high of EUR 19.21 yet still about 40 percent above the 52-week low of EUR 12.49, giving investors a picture of a stock that has recovered from last year’s lows but is now correcting from recent highs.
Evonik stock key data
- Company: Evonik Industries AG
- ISIN: DE000EVNK013
- WKN: EVNK01
- Ticker: EVK
- Trading venue: Xetra
- Price (as of September 15, 2026): 17.50 EUR
- Market capitalization: 8,000,000,000 EUR (as of September 11, 2026)
- Sector / Industry: Chemicals / Specialty Chemicals
- Index membership: MDAX
